Deoxyshikonin
CAS No. 43043-74-9
Deoxyshikonin ( Arnebin 7, Deoxyshikonin )
产品货号. M18546 CAS No. 43043-74-9
Deoxyshikonin 从软紫草 Arnebia euchroma 中分离,具有抗肿瘤活性。Deoxyshikonin增加 HMVEC-dLy 中 VEGF-C 和 VEGF-A mRNA 的表达,促进 HIF-1α 和 HIF-1β 亚基相互作用,并与 HIF 特异性 DNA 序列结合。Deoxyshikonin 在体外具有促血管生成作用。Deoxyshikonin 显示出显着的协同抗微生物活性, S. pneumonia (MIC =17μg/mL),也显示出对 MRSA 的显着抑制活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1423 | 有现货 |
|
| 10MG | ¥2261 | 有现货 |
|
| 25MG | ¥3887 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Deoxyshikonin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Deoxyshikonin 从软紫草 Arnebia euchroma 中分离,具有抗肿瘤活性。Deoxyshikonin增加 HMVEC-dLy 中 VEGF-C 和 VEGF-A mRNA 的表达,促进 HIF-1α 和 HIF-1β 亚基相互作用,并与 HIF 特异性 DNA 序列结合。Deoxyshikonin 在体外具有促血管生成作用。Deoxyshikonin 显示出显着的协同抗微生物活性, S. pneumonia (MIC =17μg/mL),也显示出对 MRSA 的显着抑制活性。
-
产品描述Deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases. Deoxyshikonin enhances the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. Deoxyshikonin and dodecyl gallate show significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and can effectively reduce nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes.
-
体外实验Cell Viability Assay Cell Line:Caco-2, HCT116, DLD-1 and HT29 cells Concentration:6.25, 12.5, 25, 50 and 100?μg/mL Incubation Time:48?h Result:At low concentration inhibited the growth of human colonic cancer cells including DLD-1, HCT-116, Caco-2 and HT29 cells. Had IC50 values of 31.00??μM at 24?h, while 10.97?μM at 48?h in HT29 cells. Apoptosis Analysis Cell Line:HT29 cells Concentration:25, 50 and 100?μg/mL Incubation Time:24 or 48?hResult:The ratio of early apoptotic cells increased from 1% to 29% in a dose-dependent manner by being treated with 0-50?μg/mL at 48?h.Cell Cycle Analysis Cell Line:HT29 cells Concentration:25, 50 and 100?μg/mL Incubation Time:48?h Result:The percentage of G0/G1 cells increased from approximately 44% to 67% in HT29 cells after treatment with 0-50?μg/mL, accompanied by a significant decrease in the percentage of cells at S and G2/M phases.Western Blot Analysis Cell Line:HT29 and DLD-1 cell lines Concentration:25, 50 and 100?μg/mL Incubation Time:48?h Result:Exerted a decrease of PI3K, p-PI3K, Akt, p-Akt308 and mTOR proteins expression in HT29 and DLD-1 cell lines.
-
体内实验Animal Model:Male BALB/c nude mice of 10-14?g with DLD-1 cells Dosage:20?mg/kg Administration:Intraperitoneal injection; every two days for a total of 13 days Result:Markedly suppressed the growth of xenograft tumours on day 5, 9 and 11 with 20?mg/kg, while there were no significant changes in body weight of the mice.
-
同义词Arnebin 7, Deoxyshikonin
-
通路Cell Cycle/DNA Damage
-
靶点DNA/RNA Synthesis
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number43043-74-9
-
分子量272.3
-
分子式C16H16O4
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 33.33 mg/mL (122.40 mM)
-
SMILESCC(=CCCC1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)C
-
化学全称1,4-Naphthalenedione, 5,8-dihydroxy-2-(4-methyl-3-pentenyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Azelaic acid
壬二酸是一种饱和二羧酸,天然存在于小麦、黑麦和大麦中。
-
Fosifloxuridine nafa...
NUC-3373 (Fosifloxuridine nafalbenamide) 是一种嘧啶核苷酸类似物,是一种胸苷酸合酶抑制剂。NUC-3373 具有抗癌活性。
-
Doxifluridine
Doxifluridine 是一种胸苷酸合成酶抑制剂。
021-51111890
购物车()
sales@molnova.cn

